Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.38 USD | -4.03% | -1.65% | +34.46% |
Business Summary
Number of employees: 52
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Adeno-Associated Viruses-based Gene Therapies
100.0
%
| 3 | 100.0 % | 15 | 100.0 % | +517.55% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 3 | 100.0 % | 15 | 100.0 % | +517.55% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sean Nolan
CEO | Chief Executive Officer | 56 | 20-02-29 |
Kamran Alam
DFI | Director of Finance/CFO | 46 | 20-07-31 |
President | 58 | 20-06-30 | |
Fred Porter
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jim Rouse
CTO | Chief Tech/Sci/R&D Officer | - | - |
Sean McAuliffe
PRN | Corporate Officer/Principal | - | 20-05-31 |
Emily McGinnis
LAW | General Counsel | - | 20-03-31 |
Tracy M. Porter
HRO | Human Resources Officer | - | 21-01-25 |
Mary Newman
PRN | Corporate Officer/Principal | 65 | 21-05-12 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Donenberg
BRD | Director/Board Member | 63 | 20-08-30 |
Sean Nolan
CEO | Chief Executive Officer | 56 | 20-02-29 |
Sean Stalfort
BRD | Director/Board Member | 54 | 23-06-20 |
President | 58 | 20-06-30 | |
Director/Board Member | 63 | 20-11-22 | |
Alison Long
BRD | Director/Board Member | 61 | Oct. 31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 187,018,275 | 152,483,105 ( 81.53 %) | 0 | 81.53 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.46% | 464M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- TSHA Stock
- Company Taysha Gene Therapies, Inc.